| [Latest] Global Golf Training Aids Market Size/Share Worth USD 4.6 Billion by 2033 at a 5.7% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) |
Globe Newswire |
04/29 |
04:30 |
| Prime Video to Become the Home of National Monday Night NHL Games in Canada Beginning in 2024-25 Season, with Prime Monday Night Hockey |
Globe Newswire |
04/25 |
11:00 |
| Sportradar to Release First Quarter Financial Results on May 15, 2024 |
Globe Newswire |
04/25 |
08:30 |
| Sportradar Appoints Craig Felenstein as Chief Financial Officer |
Globe Newswire |
04/25 |
08:00 |
| Enterome to Present Clinical Data on EO2463 in B-cell Lymphoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting |
Globe Newswire |
04/25 |
06:00 |
| HDAC Inhibitor Market to Observe Stunning Growth During the Study Period (2020?2034) | DelveInsight |
Globe Newswire |
04/24 |
13:00 |
| Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO |
Globe Newswire |
04/24 |
10:05 |
| Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO |
Globe Newswire |
04/24 |
10:00 |
| Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting |
Globe Newswire |
04/24 |
10:00 |
| Lori Kalani to Join DraftKings as First Chief Responsible Gaming Officer |
Globe Newswire |
04/22 |
09:15 |
| Gildan Activewear Announces Board Refreshment to Support CEO Vince Tyra and Gildan?s Next Phase of Sustainable Growth |
Globe Newswire |
04/22 |
05:00 |
| Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases |
Globe Newswire |
04/16 |
07:00 |
| DraftKings to Release First Quarter 2024 Results on May 2, 2024 and Host Conference Call on May 3, 2024 |
Globe Newswire |
04/15 |
16:30 |
| Hispanic C-Suite Corporate Council (HC3) to Host NFL Draft Hispanic Celebration |
Globe Newswire |
04/15 |
12:00 |
| Verizon Business, AWS, and the NHL demo 5G-enabled cloud broadcasting at the 2024 NAB Show |
Globe Newswire |
04/14 |
11:00 |
| Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics |
Globe Newswire |
04/11 |
07:00 |
| Verizon Business to demonstrate cutting-edge media and entertainment technology at NAB 2024 Verizon Business to showcase its media and entertainment technology at NAB April 13-17 at booth #W2042 |
Globe Newswire |
04/10 |
09:00 |
| Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update |
Globe Newswire |
04/10 |
07:00 |
| ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (?R/R B-NHL?) |
Globe Newswire |
04/09 |
17:30 |
| Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies |
Globe Newswire |
04/09 |
13:15 |
| New Jersey Devils and Prudential Center announce extended partnership with Verizon |
Globe Newswire |
04/09 |
09:30 |
| Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies? |
Globe Newswire |
04/08 |
07:00 |
| Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 |
Globe Newswire |
04/04 |
16:01 |
| Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus |
Globe Newswire |
04/04 |
16:00 |
| ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA? in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma |
Globe Newswire |
04/04 |
07:00 |
